Genprex, Inc.
GNPXHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeGenprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Valued at $1.5M, GNPX is a micro-cap name in its sector. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes.
Market Cap
$1.5M
Beta
-0.97
P/E (TTM)
—
P/E (Fwd)
-0.83
EPS (TTM)
$-8.62
EPS (Fwd)
$-2.18
ROE
-203.9%
ROA
-94.5%
Cash
$15.2M
Total Debt
$0
Free CF
-$10.6M
52W Change
-99.1%
Annual Financials
Cash vs Debt
Where GNPX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, GNPX finished 84.93% below its 150-day moving average ($13.67) and 90.84% below its 200-day moving average ($22.48). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GNPX overbought or oversold?
At the October 20, 2026 close, GNPX's RSI(14) was 24.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Genprex, Inc. reports $15.2M in cash and $0 in total debt. Free cash flow is running at -$10.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -203.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
GNPX's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing GNPX.